Overview

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)

Status:
Recruiting

Trial end date:
2023-07-14

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in COPD participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 57 weeks, consisting of 2 screening visits, run-in period, and a 52-week intervention period. 800-1000 participants will be randomized in 1:1 ratio to receive mepolizumab 100 milligram (mg) or placebo every 4 weeks for a total of 13 doses.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

PPD